Back to top

Analyst Blog

NextGxDx Inc., the comprehensive online marketplace for genetic testing, recently announced its partnership with athenahealth Inc, (ATHN - Analyst Report) to deliver an integrated platform that will help clinicians to improve genetic test ordering. The new clinical interface for genetic testing will add to athenahealth's existing suite of solutions.

athenahealth is one of the leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination. The collaboration of the two companies will enable ATHN’s clinicians to avail genetic testing through an integrated EHR platform.

NextGxDx believes that all the underlying challenges in the healthcare industry can be overcome through the adoption of superior technology. Genetic testing is one such area where state-of-the-art technology can improve efficiency, while reducing the complexities encountered in the diagnostic process. However, despite its popularity and increasing applicability to patient outcomes, genetic order testing remains underutilized due to its growth rate.

NextGxDx online tool, acts as a one stop shop to allow easier search, comparison and ordering of genetic tests. The online platform is linked with an intuitive user interface, thereby enabling physicians and other health care professionals to access the current date listings of all genetic tests from CLIA certified laboratories, order tests online, and receive results electronically. Additionally, the bioinformatics team of the company utilizes proprietary tools to update and organize test data.

The single window network of NextGxDx offers clinicians a broad spectrum to order testing from, as it showcases NextGxDx affiliated labs within athenaClinicals, athenahealth's Best in KLAS EHR service, thus streamlining the genetic testing workflow.

Recently NextGxDx formed an alliance to add Cancer Genetics Inc. (CGIX - Snapshot Report), Inc. to Genetic Testing Platform. It was seen that Cancer Genetics, had a catalog of more than 100 regulatory approved oncology testing products and solutions for easy search, comparison and ordering. Moreover, genetic testing within oncology holds immense future potential as cancer–testing is emerging as a rapidly growing market worldwide.

Currently, ATHN carries a Zacks Rank #5 (Sell). Other medical information systems stocks that are worth a look include Streamline Health Solutions, Inc. (STRM - Snapshot Report), with a Zacks Rank #2 (Buy) and medical services stocks that can be considered include BG Medicine, Inc. (BGMD),and Cancer Genetics, Inc. (CGIX - Snapshot Report) with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.38 +5.05%
CHYRONHEGO… CHYR 2.85 +4.78%
RF MICRO DE… RFMD 12.29 +4.46%
VASCO DATA… VDSI 14.70 +4.18%
ERBA DIAGNO… ERB 3.70 +2.49%